Amarin gains positive opinion from Spanish Drug Pricing Committee for national reimbursement of Vazkepa in Spain
Amarin has announced that the Spanish Drug Pricing Committee has recommended the national reimbursement of Vazkepa (icosapent ethyl) in Spain to reduce the risk of cardiovascular (CV) events in patients with high CV risk.
This decision follows the most recent meeting of the Committee on the 24July 2023.
Professor Luis Rodriguez Padial, cardiologist and elected president of the Spanish Society of Cardiology, commented: “Cardiovascular disease is still one of Spain’s leading causes of death and patients with this disease need access to new treatments that can reduce their risk of having another event. I am very pleased to see that our health authorities are now making icosapent ethyl available in Spain which has shown to significantly reduce cardiovascular risk and help to prevent future heart attacks or strokes in these high cardiovascular risk patients.”
Patrick Holt, president and CEO of Amarin, added: “The positive recommendation for Vazkepa in Spain is an important step for the thousands of cardiovascular patients who now have access to a new, innovative treatment option to reduce their cardiovascular risk based on the robust clinical data and evidence from the REDUCE-IT study. Our team in Spain will now be laser-focused on supporting efforts to reach healthcare professionals and drive awareness and adoption of this important new treatment for patients. I look forward to our launch efforts to accelerate growth in this important market.”
AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk …
Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a …